Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients
Young Kwang Chae(Northwestern University), Manali Bhave(Northwestern University), Wade T. Iams(Vanderbilt University Medical Center), Jonathan F. Anker(Tisch Hospital), Carlos Galvez(Northwestern University)
Cited by 47
Related Papers
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
|Journal for ImmunoTherapy of Cancer|2018|468
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|459
Immunotherapeutic approaches for small-cell lung cancer
|Nature Reviews Clinical Oncology|2020|346